Obesity Epidemic: Pharmaceutical Weight Loss.

Mar 2, 2017Rhode Island medical journal (2013)

Pharmaceutical Weight Loss in the Obesity Epidemic

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗

Abstract

Obesity is defined as a body mass index (BMI) greater than 30.0 kg/m2.

Obesity is classified as a chronic disease characterized by excess body fat.
Increased awareness of prevention has spurred the development of new pharmaceutical treatments since 2012.
Effective obesity treatment involves a personalized, multi-disciplinary approach.
A healthy and supportive lifestyle is essential for maintaining weight loss.

AI simplified

Obesity is a chronic disease universally defined as an excess of adipose tissue resulting in body mass index (BMI) > 30.0 kg/m2. Over the past few years, the concept of prevention has gained increased awareness, thus leading to the development of additional pharmaceutical options for the treatment of obesity since 2012. Treating obesity revolves around an individualized, multi-disciplinary approach with additional focus on a healthy and supportive lifestyle to maintain the weight loss. [Full article available at http://rimed.org/rimedicaljournal-2017-03.asp].

Obesity Epidemic: Pharmaceutical Weight Loss.

Abstract

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief